Cisplatin-based neoadjuvant chemotherapy (NAC) is recommended prior to radical cystectomy for muscle-invasive bladder cancer (MIBC) patients. Despite a 5-10% survival benefit, some patients do not respond and experience substantial toxicity and delay in surgery.
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU medical oncologist at Dana Farber Cancer Institute in Boston. I’m excited to have here with me today, a good friend and colleague, Michael Morris, who is the prostate cancer section head and a GU medical oncologist at Memorial Sloan Kettering in New York, […]
– KEYTRUDA® Plus LENVIMA® Is Now Approved for Two Types of Cancer, Including Advanced RCC – Based on Phase 3 CLEAR/KEYNOTE-581 Trial, KEYTRUDA Plus LENVIMA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib San Francisco, CA (UroToday.com) — Merck, known as MSD outside the United States and Canada, and Eisai announced […]
South Australian patients with cancer will benefit from world-class cancer research and new treatments with the appointment of three globally-lauded scientists to the University of Adelaide’s South Australian immunoGENomics Cancer Institute (SAiGENCI). San Francisco, CA (UroToday.com) — Distinguished researchers Professor Jose Polo and Associate Professor Luciano Martelotto have also been appointed to senior roles in the […]
Screening for prostate cancer using prostate-specific antigen (PSA) testing can lead to problems of underdiagnosis and overdiagnosis. Short, noncontrast magnetic resonance imaging (MRI) or transrectal ultrasonography might overcome these limitations.
To investigate gene alterations as diagnostic and prognostic markers in upper tract urothelial carcinoma (UTUC). Patients with UTUC who underwent nephroureterectomy in 2005-2012 were followed until November 2020.
One cycle of adjuvant chemotherapy with bleomycin, etoposide and cisplatin (BEP) has shown superiority in recurrence-free survival over retroperitoneal lymph node dissection (RPLND) in patients with clinical stage (CS) I non-seminomatous germ cell tumours (NSGCTs) of the testis in the setting of a phase III trial.
The role of renal biopsy prior to surgical intervention for a renal mass remains controversial despite the fact that for all other urological organs except the testicle, biopsy inevitably precedes treatment as is true for all other specialties dealing with solid masses (e.
Cancer-associated fibroblasts (CAF) are highly prevalent cells in the tumor microenvironment in clear cell renal cell carcinoma (ccRCC). CAFs exhibit a pro-tumor effect in vitro and have been implicated in tumor cell proliferation, metastasis, and treatment resistance.
Real-world evidence suggest that next generation hormonal agents (NHAs) abiraterone and enzalutamide were preferred as first-line (1L) therapies for metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) pre-2020, with chemotherapies, particularly docetaxel, being preferred in subsequent lines (2L+).
